Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? (2016)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.atherosclerosis.2016.02.018
- Subjects: MUTAÇÃO GENÉTICA; LIPÍDEOS; ANTICORPOS MONOCLONAIS; HIPERCOLESTEROLEMIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Atherosclerosis
- ISSN: 0021-9150
- Volume/Número/Paginação/Ano: v. 248, n. 1, p. 62-75, 2016
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
BANERJEE, Yajnavalka et al. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. Atherosclerosis, v. 248, n. 1, p. 62-75, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2016.02.018. Acesso em: 18 abr. 2024. -
APA
Banerjee, Y., Santos, R. D., Al-Rasadi, K., & Rizzo, M. (2016). Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Atherosclerosis, 248( 1), 62-75. doi:10.1016/j.atherosclerosis.2016.02.018 -
NLM
Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? [Internet]. Atherosclerosis. 2016 ; 248( 1): 62-75.[citado 2024 abr. 18 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2016.02.018 -
Vancouver
Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? [Internet]. Atherosclerosis. 2016 ; 248( 1): 62-75.[citado 2024 abr. 18 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2016.02.018 - Foi com muita satisfação que recebemos o convite dos ...[Apresentação]
- Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- Elevated uric acid, the metabolic syndrome and cardiovascular disease [Editorial]: cause, consequence, or just a not so innocent bystander?
- Lipid-lowering treatment for homozygous familial hypercholesterolaemia [Carta]
- Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease
- A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
Informações sobre o DOI: 10.1016/j.atherosclerosis.2016.02.018 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
